FORTRESS (Fosfomycin i.v. for treatment of severely infect
Research type
Research Study
Full title
A European, multicentre, non-comparative, non-interventional, prospective clinical registry to evaluate the clinical outcome and safety of the treatment of severely infected patients with fosfomycin IV.
IRAS ID
254279
Contact name
Abhijit M Bal
Contact email
Sponsor organisation
InfectoPharm Arzneimittel und Consilium GmbH
Duration of Study in the UK
1 years, 4 months, 13 days
Research summary
The antibiotic fosfomycin is considered to be a valuable agent for treatment of patients with high risk of resistant pathogens in initial empirical combination therapy, as targeted combination therapy in difficult to treat or deep seated infections or as rescue therapy in patients with multi-drug resistant pathogens. Fosfomycin has been used to treat serious bacterial infections in several European countries. For example bone infections, urinary tract infections, respiratory, tract infections, sepsis.
In this study we will document data from participants with serious bacterial infections and look at the effectiveness and safety of fosfomycin.
REC name
North West - Haydock Research Ethics Committee
REC reference
18/NW/0696
Date of REC Opinion
10 Dec 2018
REC opinion
Further Information Favourable Opinion